<DOC>
	<DOCNO>NCT01928160</DOCNO>
	<brief_summary>This randomized phase II trial study well pemetrexed disodium carboplatin cisplatin without erlotinib hydrochloride work treat patient epidermal growth factor receptor ( EGFR ) mutant positive stage IV non-small cell lung cancer acquire resistance first-line therapy erlotinib hydrochloride gefitinib . In patient develop resistance first-line therapy EGFR tyrosine kinase inhibitor ( TKIs ) drug usually stop patient switched chemotherapy . Drugs use chemotherapy , pemetrexed disodium , carboplatin , cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Erlotinib hydrochloride may stop growth tumor cell block enzymes need cell growth . It yet know whether pemetrexed disodium carboplatin cisplatin effective without erlotinib hydrochloride treat patient EGFR mutant non-small cell lung cancer acquire resistance EGFR TKIs .</brief_summary>
	<brief_title>Pemetrexed Disodium Carboplatin Cisplatin With Without Erlotinib Hydrochloride Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant First-Line Therapy With Erlotinib Hydrochloride Gefitinib</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare effect chemotherapy plus erlotinib ( erlotinib hydrochloride ) vs. chemotherapy alone progression-free survival ( PFS ) non-small cell lung cancer ( NSCLC ) patient harbor activate endothelial growth factor receptor ( EGFR ) mutation develop acquire resistance first-line therapy erlotinib gefitinib . SECONDARY OBJECTIVES : I . To determine overall survival ( OS ) response rate patient population . II . To assess safety erlotinib combination chemotherapy patient population . TERTIARY OBJECTIVES : I . To determine whether presence T790M resistance mutation use predict patient benefit addition erlotinib chemotherapy . II . To determine patient NSCLC harbor activate EGFR mutation develop acquire resistance EGFR tyrosine-kinase inhibitor ( TKIs ) develop additional mutations/genetic alteration progression . III . To determine whether additional biomarkers ( e.g. , mesenchymal-epithelial transition [ MET ] amplification , EGFR mutation detect circulate free deoxyribonucleic acid [ DNA ] ) predict response second-line therapy patient population . IV . To determine progression-free survival ( PFS ) patient chemotherapy alone arm cross erlotinib progression compare patient combination chemotherapy arm ( erlotinib plus chemotherapy ) switch chemotherapy choice ( without erlotinib ) progression . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive erlotinib hydrochloride orally ( PO ) daily ( QD ) day 1-21 , pemetrexed disodium intravenously ( IV ) carboplatin IV cisplatin IV day 1 . Treatment repeat every 21 day 4 course . Patients receive maintenance erlotinib hydrochloride orally ( PO ) daily ( QD ) day 1-21 pemetrexed disodium IV day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . ARM II : Patients receive pemetrexed disodium carboplatin cisplatin Arm I . Treatment repeat every 21 day 4 course . Patients receive maintenance pemetrexed disodium Arm I . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow death .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Signed informed consent prior initiation studyspecific procedure treatment . Informed Consent Form must sign within 14 day study treatment initiation . Age &gt; 18 year Able willing comply protocol Histologically cytologicallyconfirmed Stage IV NSCLC EGFR exon19 deletion L858R mutation Must receive least 6 month firstline therapy erlotinib gefitinib Clinical evidence progression firstline EGFR TKI therapy Adequate hematological function within 7 day study treatment initiation : 1 . Absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L AND 2 . Platelet count &gt; 100 x 109/L AND 3 . Hemoglobin &gt; 9 g/dL ( may transfuse maintain exceed level ) Adequate liver function within 7 day study treatment initiation : 1 . Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) AND 2 . AST ALT &lt; 2.5 x ULN patient without liver metastasis ; &lt; 5 x ULN patient liver metastasis Adequate renal function within 7 day study treatment initiation : a. Serum creatinine &lt; 1.25 x ULN calculate creatinine clearance &gt; 50 mL/min ( Creatinine clearance may calculate per institutional standard . ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 within 7 day study treatment initiation Patients stable , treated brain metastasis eligible study participation may stable dose steroid screen . Anticonvulsants ( stable dose ) allow . Radiotherapy stereotactic radiosurgery brain must complete least 28 day prior randomization Female patient must pregnant breastfeeding . Female patient childbearing potential agree use effective , nonhormonal mean contraception ( intrauterine contraceptive device , barrier method contraception conjunction spermicidal jelly surgically sterile ) study period least 6 month follow last administration study drug . Female patient intact uterus ( unless amenorrhoeic last 12 month ) must negative serum pregnancy test within 7 day prior randomization study . Fertile male patient must agree use effective contraception study period least 3 month follow last administration study drug Any prior treatment metastatic NSCLC erlotinib gefitinib . Prior adjuvant chemotherapy concurrent chemoradiation therapy allow complete least 12 month prior trial enrollment Radiotherapy brain within 28 day prior randomization , radiotherapy site 14 day prior randomization Clinically significant ( i.e. , active ) cardiovascular disease ( e.g. , cerebrovascular accident myocardial infarction within 6 month prior randomization ) , unstable angina , congestive heart failure ( New York Heart Association Class &gt; II ) , serious cardiac arrhythmia , uncontrolled medication may interfere administration study treatment Treatment investigational agent participation another clinical trial combine erlotinib second therapy unless patient placebo . Malignancies NSCLC within 3 year prior randomization , except adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat radiation surgically curative intent , ductal carcinoma situ treat surgically curative intent Evidence disease , neurological metabolic dysfunction , physical examination find laboratory find give reasonable suspicion disease condition contraindicate use investigational drug put patient high risk treatmentrelated complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Non-small cell lung cancer , EGFR mutation , erlotinib acquire resistance</keyword>
</DOC>